Letrozole for patients with polycystic ovary syndrome A retrospective study

This retrospective study investigated the efficacy and safety of letrozole for patients with polycystic ovary syndrome (PCOS). Totally, 136 cases of infertility women with PCOS were analyzed. Of those, 68 patients received letrozole, and were assigned to Letrozole group. The other 68 cases received clomiphene, and were assigned to clomiphene group. Patients in both groups were treated up to 5 treatment cycles. The primary endpoint included infant outcomes. The secondary endpoints consisted of the number of women in conception, pregnancy, pregnancy loss, and ovulation. In addition, any kinds of adverse events were also recorded. Cases in the Letrozole group did not show better outcomes neither in primary endpoint (live birth, P=.11; birth weight, P=.95; infant gender, P=.85), nor in secondary endpoints (the number of women in conception, P=.07; pregnancy, P=.12; pregnancy loss, P=.47; pregnancy loss in first trimester, P=.70; and ovulation, P=.09), compared with cases in the clomiphene group. Moreover, no adverse events differ significantly between 2 groups. This study demonstrated that the efficacy of letrozole is not superior to the clomiphene in patients with PCOS.